Medical Term for Man Boobs: Gynaecomastia

The medical term for man boobs is gynaecomastia, a condition involving the benign enlargement of glandular breast tissue in males. Distinct from pseudogynaecomastia, which is caused by excess fatty tissue, true gynaecomastia involves actual glandular growth beneath the nipple and areola. It can affect males at any age and arises from a hormonal imbalance between oestrogen and androgens. While usually benign, gynaecomastia can cause significant psychological distress. This article explains the causes, diagnosis, NHS treatment options, and when to seek medical advice.

What is the medical term for man boobs?

The medical term for man boobs is gynaecomastia, referring to benign glandular breast tissue enlargement in males, distinct from pseudogynaecomastia, which involves excess chest fat rather than glandular growth.

The medical term for man boobs is gynaecomastia, which refers to the benign enlargement of glandular breast tissue in males. The word derives from the Greek for "woman" and "breast" and describes a condition that is distinct from the accumulation of fatty tissue in the chest area, which is sometimes called pseudogynaecomastia. True gynaecomastia involves the growth of actual glandular tissue beneath the nipple and areola, rather than simply an increase in subcutaneous fat. Clinically, this glandular tissue typically feels like a firm, rubbery disc centred directly under the nipple, whereas pseudogynaecomastia presents as softer, more diffuse fatty tissue across the chest without a discrete subareolar mass.^[1]

Gynaecomastia is more common than many people realise. It can affect males at any age, from newborns and adolescents through to older men, and in many cases it resolves without treatment. The NHS recognises it as a benign condition in the majority of cases, though it can cause significant psychological distress, self-consciousness and discomfort for those affected.

It is important to distinguish gynaecomastia from pseudogynaecomastia, as the two conditions have different underlying causes and may require different approaches. Pseudogynaecomastia is associated with excess body fat rather than glandular proliferation and is not a hormonal condition in the same way; weight loss and lifestyle changes may improve pseudogynaecomastia, whereas true glandular tissue may not fully regress without addressing the underlying cause. A clinician can usually differentiate between the two through physical examination, though further investigation is sometimes needed to confirm the diagnosis and identify any underlying cause.

What causes gynaecomastia in men?

Gynaecomastia is caused by an imbalance between oestrogen and androgen activity; triggers include puberty, ageing, obesity, medicines such as spironolactone or finasteride, and conditions such as hypogonadism or chronic liver disease.

Gynaecomastia is caused by an imbalance between oestrogen and androgen (testosterone) activity in male breast tissue, which stimulates glandular growth.^[4][5] This hormonal imbalance can arise from a wide range of physiological, pharmacological and pathological factors. In many cases, no single identifiable cause is found, and the condition is described as idiopathic.

Physiological gynaecomastia occurs at predictable life stages. In newborns, it results from maternal oestrogen crossing the placenta. In adolescent boys, it is common during puberty as oestrogen levels temporarily rise relative to testosterone; the condition is usually self-limiting and resolves within one to two years. In older men, declining testosterone levels alongside relatively stable oestrogen can again tip the balance. Obesity can also contribute through increased peripheral conversion of androgens to oestrogen via aromatisation.^[6]

A number of medicines are well-recognised causes of gynaecomastia, including:

• Anabolic steroids and androgens, which can be converted to oestrogen in the body

• Anti-androgens used in prostate cancer treatment (for example, bicalutamide)

• 5-alpha reductase inhibitors such as finasteride and dutasteride

• Spironolactone, a diuretic with anti-androgenic properties

• Cimetidine (an H2-receptor antagonist)

• Some antipsychotics and antidepressants

• Digoxin and some antiretroviral medicines

• Recreational drugs, including alcohol

• Ketoconazole and certain other antifungals

This list is not exhaustive. The Specialist Pharmacy Service (SPS) publishes UK-focused guidance on medicines associated with gynaecomastia, which clinicians and pharmacists can consult for a more comprehensive review.

Underlying health conditions can also be responsible. These include hypogonadism (including Klinefelter syndrome), hyperthyroidism, chronic liver disease, chronic kidney disease, malnutrition or re-feeding states, and, rarely, testicular, adrenal or other tumours that secrete hormones or human chorionic gonadotrophin (hCG). Because some causes require specific treatment, a thorough clinical assessment is always warranted when gynaecomastia is identified.

How is gynaecomastia diagnosed in the UK?

Diagnosis combines clinical history, physical examination and blood tests including testosterone, LH, FSH, oestradiol, prolactin and hCG; imaging or urgent breast clinic referral follows if malignancy is suspected.

Gynaecomastia is diagnosed through a combination of clinical history, physical examination and targeted investigations. NICE Clinical Knowledge Summaries (CKS) and NHS clinical pathways provide guidance on the diagnostic approach. A GP will typically begin by taking a detailed history, including any medicines (prescribed, over-the-counter or recreational), family history, and the onset and progression of the breast tissue change. Physical examination focuses on distinguishing firm, rubbery glandular tissue beneath the nipple from softer fatty tissue, and on checking for any asymmetry, skin changes or lymph node enlargement that might suggest a more serious cause.

Blood tests are commonly requested to assess hormone levels. These typically include total testosterone (ideally measured in the morning, when levels are highest), luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, thyroid function and human chorionic gonadotrophin (hCG), the last of which is important to detect hCG-secreting tumours. Sex hormone-binding globulin (SHBG) may also be measured where available. Liver and kidney function tests may be performed, as these organs play a role in hormone metabolism. In adolescents with typical pubertal gynaecomastia and no concerning features, extensive investigation is often not necessary.

Imaging may be arranged where there is clinical uncertainty. Breast ultrasound can help differentiate glandular tissue from fat and identify any discrete masses. Mammography is occasionally used in older men. If a testicular tumour is suspected, scrotal ultrasound is recommended. Where findings are suspicious, referral to a breast clinic for triple assessment (clinical examination, imaging and biopsy where indicated) is appropriate.

Referral to an endocrinologist, urologist or breast surgeon may follow depending on the findings. Under NICE guideline NG12 (Suspected cancer: recognition and referral), an urgent two-week-wait referral to a breast clinic is indicated where a clinician suspects malignancy.^[2] Male breast cancer is rare, accounting for a small minority of all breast cancer diagnoses in the UK; Cancer Research UK data indicate it represents less than one per cent of all breast cancers diagnosed in the UK each year.^[11]

What treatment options are available on the NHS?

NHS treatment depends on cause and severity; options include watchful waiting, addressing causative medicines, off-label SERMs in specialist settings, and surgery, though surgical funding requires demonstrable clinical need.

Treatment for gynaecomastia on the NHS depends on the underlying cause, the duration of the condition and the degree of distress or physical discomfort it causes. In many cases, particularly in adolescents with pubertal gynaecomastia, watchful waiting is the first approach, as the condition often resolves spontaneously within one to two years without any intervention.

Where a causative medicine is identified, reviewing or stopping that medicine (under medical supervision) may lead to regression of breast tissue, particularly if the condition is caught early. Treating an underlying medical condition, such as hyperthyroidism or hypogonadism, can similarly result in improvement.

Medical therapy is not routinely commissioned on the NHS for gynaecomastia, and no medicine currently holds a UK marketing authorisation specifically for this indication.^[7] Commissioning decisions vary across Integrated Care Boards (ICBs) in England and across the devolved health services in Wales, Scotland and Northern Ireland, so access to specialist treatment may differ depending on where a person lives. Tamoxifen and raloxifene, both selective oestrogen receptor modulators (SERMs), are sometimes used off-label in specialist settings, particularly for painful or persistent gynaecomastia of recent onset. Evidence suggests SERMs are most effective when breast tissue has been present for less than six to twelve months; longstanding, fibrotic glandular tissue is less likely to respond. Where a specialist considers off-label SERM treatment appropriate, this should involve shared decision-making and documented informed consent. Prescribing decisions rest with the specialist and the relevant ICB commissioning policy.

Surgical treatment, typically subcutaneous mastectomy or liposuction, may be considered for longstanding gynaecomastia that has not responded to other measures and is causing significant psychological or physical impact. NHS England's Evidence-Based Interventions programme and local ICB policies set out eligibility criteria, which may include assessment of psychological impact. NHS funding for surgery is not universally available, and many patients are advised that it is not routinely funded unless there is demonstrable clinical need beyond cosmetic concern. Private surgical options exist for those who do not meet NHS thresholds, and costs vary considerably between providers.

When should you see a GP about chest swelling?

See a GP promptly for any hard, irregular or rapidly changing breast lump, nipple discharge, skin changes or unilateral swelling; men aged 50 or over with these features should be referred urgently via the two-week-wait pathway.

You should see a GP about chest swelling if you notice any new, persistent or rapidly changing breast tissue, particularly if it is accompanied by pain, nipple discharge or skin changes. While gynaecomastia is almost always benign, some presentations warrant prompt assessment to rule out less common but more serious causes, including male breast cancer or hormone-secreting tumours.

Contact your GP promptly if you experience any of the following:

• A hard, irregular or fixed lump in the breast or chest area

• Nipple discharge, especially if it is bloodstained or occurs without squeezing

• Skin dimpling, puckering or redness over the breast

• Swelling in one breast only, particularly in an older man

• Breast changes alongside unexplained weight loss, fatigue or testicular changes (such as a lump or pain in the testicle)

• Breast enlargement that develops rapidly or continues to grow

• Persistent headaches or visual disturbance alongside breast changes, which may suggest a pituitary cause such as hyperprolactinaemia^[9][10]

Under NICE guideline NG12, men aged 50 or over with a unilateral, firm subareolar mass with or without nipple changes or skin changes should be referred urgently via the two-week-wait pathway for suspected breast cancer.^[2]

Adolescent boys with typical bilateral, mildly tender breast tissue during puberty do not usually need urgent review, but a GP appointment is still worthwhile for reassurance and to confirm the diagnosis. Men who are taking a new medicine and notice breast changes should speak to their GP or pharmacist before stopping any prescribed treatment.

If you experience any side effects from a medicine that you believe may be contributing to breast tissue changes, these can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. For urgent symptoms such as a rapidly enlarging painful mass or signs of systemic illness, contact NHS 111 for advice, or attend your GP as soon as possible. Only attend A&E or call 999 if you have a life-threatening emergency unrelated to the breast change itself.

Scientific References

1. Gynaecomastia.
2. Suspected cancer: recognition and referral (NG12).
3. Drug-induced gynecomastia: an evidence-based review.
4. Drug-induced gynecomastia. Pharmacotherapy..
5. Estrogens and the human male. Annual Review of Medicine..
6. Aromatase deficiency in a male patient – case report and review of the literature. Bone..
7. Marketing authorisations: lists of granted licences.
8. Breast reduction (male).
9. Prolactinoma in the male: physiopathological, clinical, and therapeutic features. Minerva Endocrinologica..
10. Clinical and radiological findings in macroprolactinemia. Endocrine..
11. Breast cancer – Treatment summaries. BNF..

Frequently Asked Questions